Insilico Medicine (HKEX: 3696) announced that first-in-human Phase 1 trial data for ISM6331, its AI-designed pan-TEAD inhibitor, has been accepted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE